Pacira BioSciences Inc. (NASDAQ: PCRX) confirmed that DOMA Perpetual Capital Management LLC has nominated three director candidates for election at the company's 2026 annual meeting of stockholders.

The pharmaceutical company reported treating 2.5 million patients with its products in 2025 and increased EXPAREL volume growth to 6.2% year-over-year, compared to 3.6% in 2024. The company achieved record gross margins of 79% GAAP and 81% non-GAAP in 2025.

Pacira secured a settlement of its patent infringement lawsuit and expanded its intellectual property portfolio to 21 Orange Book-listed patents across two families protecting the EXPAREL franchise. The company executed $150 million in stock repurchases in 2025, reducing outstanding shares from 47 million to 41 million.

The company said its board and management team have met with DOMA 12 times since CEO Frank Lee took his position in January 2024. According to the statement, DOMA has not provided new insights regarding strategy or operations that are not already being evaluated as part of Pacira's 5x30 growth strategy.

Pacira's board will review the proposed nominees through its established processes and will present recommendations in the definitive proxy statement to be filed with the Securities and Exchange Commission. The annual meeting date has not been announced, and shareholders are not required to take action at this time.

The company operates three commercial-stage non-opioid treatments: EXPAREL for postsurgical pain management, ZILRETTA for osteoarthritis knee pain, and iovera for drug-free pain control.